Review: Adverse Event Rate 8.8 Percent With RFA in Barrett's

This article originally appeared here.
Share this content:
Review: Adverse Event Rate 8.8 Percent With RFA in Barrett's
Review: Adverse Event Rate 8.8 Percent With RFA in Barrett's

MONDAY, July 25, 2016 (HealthDay News) -- For patients with Barrett's esophagus with dysplasia, the pooled rate of all adverse events from radiofrequency ablation (RFA) with or without endoscopic mucosal resection (EMR) is 8.8 percent, with increased risk for RFA with versus without EMR, according to a review published in the August issue of Clinical Gastroenterology and Hepatology.

Bashar J. Qumseya, M.D., from Archbold Medical Group/Florida State University in Thomasville, Ga., and colleagues conducted a systematic review and meta-analysis to examine the rate of adverse events associated with RFA with and without EMR. Data were included from 37 studies with 9,200 patients.

The researchers found that there was a pooled rate of 8.8 percent for all adverse events from RFA, with or without EMR; 5.6, 1.0, and 0.6 percent developed strictures, had bleeding, and developed a perforation, respectively. The relative risk for adverse events was significantly higher for RFA with EMR in studies that compared RFA with versus without EMR (4.4; P = 0.015). Compared with retrospective studies, prospective studies had a trend toward higher proportions of adverse events (11.3 versus 7.8 percent; P = 0.20). Barrett's esophagus length and baseline histology were also associated with adverse events.

"Endoscopists should discuss these risks with patients before endoscopic eradication therapy," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »